By
Trending Posts
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring…
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus…
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating…
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment…
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
Is Johnson & Johnson Preparing to Divest DePuy…
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular…
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Can Foundation Medicine and Manifold Redefine Precision Oncology…
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics…
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Can Insilico Medicine and China Medical System Accelerate…
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
Trending Posts
Latest Stories
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring Orna Therapeutics to Revolutionize Autoimmune Treatments
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1 Leadership?
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating the Competitive Battle in Prostate Cancer Therapeutics?
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1…
Gallery
